Back Back
Cell No. : Cell Name
RCB0805 : Ba/F3  update : 2022/03/24
CommentIL-3 dependent pro B cell line. Conditioned medium. Information.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Todokoro, Kazuo
Year of deposit 1992
Animal mouse < Mammals
Strain name C3H
Tissue bone marrow
Classification other
Memo_1 Mycoplasma was eliminated with MC-210.
Lifespan infinite
Morphology lymphocyte-like
Cellosaurus(Expasy) CVCL_0161
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Medium and additives RPMI1640 + 10% FBS + 10% (RCB0035 WEHI-3 conditioned medium)
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 10 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
SSLP(mouse) OK
Isozyme LD, NP
deposit info
lot info
Reference information Reference 3
User's Publication 107

To topTop
4829  Daley GQ1, Baltimore D.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.  Proc Natl Acad Sci U S A  1988  85(23):9312-6  PubMed ID: 3143116   DOI: 10.1073/pnas.85.23.9312
4828  Palacios R, Steinmetz M.  Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.  Cell  1985  41(3):727-34  PubMed ID: 3924409   DOI: 10.1016/s0092-8674(85)80053-2
4827  Palacios R, Henson G, Steinmetz M, McKearn JP.  Interleukin-3 supports growth of mouse pre-B-cell clones in vitro.  Nature  1984  309(5964):126-31  PubMed ID: 6201749   DOI: 10.1038/309126a0

To topTop
User's Publication
20414  Miyauchi M, Sasaki K, Kagoya Y, Taoka K, Masamoto Y, Yamazaki S, Arai S, Mizuno H, Kurokawa M.  CAMK2G is identified as a novel therapeutic target for myelofibrosis.  Blood Adv  2022    PubMed ID: 34521112   DOI: 10.1182/bloodadvances.2020003303
16227  Kazuya Sumi, Kenji Tago, Yosuke Nakazawa, Kyoko Takahashi, Tomoyuki Ohe, Tadahiko Mashino, Megumi Funakoshi-Tago  Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells  Int J Mol Sci  2022  23(2):749  PubMed ID: 35054935   DOI: 10.3390/ijms23020749
16427  Koga T, Suda K, Mitsudomi T.  Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer  Cancer Sci  2022  113(3):815-827  PubMed ID: 34997674   DOI: 10.1111/cas.15263
20617  Miura T, Kawano M, Takahashi K, Yuasa N, Habu M, Kimura F, Imamura T, Nakayama F.  High-Sulfated Hyaluronic Acid Ameliorates Radiation-Induced Intestinal Damage Without Blood Anticoagulation.  Adv Radiat Oncol  2022  7(3):100900  PubMed ID: 35295873   DOI: 10.1016/j.adro.2022.100900
20731  Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BY, Gainor JF, Lin JJ, Yoda S, Hata AN.  Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.  Nat Cancer  2022    PubMed ID: 35726063   DOI: 10.1038/s43018-022-00399-6
16770  Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T.  Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation  J Hematol Oncol  2022  15(1):79  PubMed ID: 35690785   DOI: 10.1186/s13045-022-01299-z
20905  Kwak C, Park C, Ko M, Im CY, Moon H, Park YH, Kim SY, Lee S, Kang MG, Kwon HJ, Hong E, Seo JK, Rhee HW.  Identification of proteomic landscape of drug-binding proteins in live cells by proximity-dependent target ID.  Cell Chem Biol  2022    PubMed ID: 36272407   DOI: 10.1016/j.chembiol.2022.10.001
20910  Kimura Y, Kashima D, Kawahara M.  A growth-based platform for detecting domain-peptide interactions in the cytoplasm of mammalian cells.  Sci Rep  2022  12(1):18028  PubMed ID: 36302843   DOI: 10.1038/s41598-022-22770-4
20920  Okuda H, Miyamoto R, Takahashi S, Kawamura T, Ichikawa J, Harada I, Tamura T, Yokoyama A.  RNA-binding proteins of KHDRBS and IGF2BP families control the oncogenic activity of MLL-AF4.  Nat Commun  2022  13(1):6688  PubMed ID: 36335100   DOI: 10.1038/s41467-022-34558-1
20930  Mendivil-Perez M, Jimenez-Del-Rio M, Velez-Pardo C.  TPEN/TPGS (T2) combo dramatically reduces Philadelphia chromosome-positive pro-lymphoblastic B leukemia in BALB/c mice.  Med Oncol  2022  40(1):15  PubMed ID: 36352172   DOI: 10.1007/s12032-022-01873-y
20107  Jia W, Kong L, Kidoya H, Naito H, Muramatsu F, Hayashi Y, Hsieh HY, Yamakawa D, Hsu DK, Liu FT, Takakura N.  Indispensable role of Galectin-3 in promoting quiescence of hematopoietic stem cells.  Nat Commun  2021  12(1):2118  PubMed ID: 33837181   DOI: 10.1038/s41467-021-22346-2
20184  Kashima D, Kawahara M.  Evolution of KIPPIS as a versatile platform for evaluating intracellularly functional peptide aptamers.  Sci Rep  2021  11(1):11758  PubMed ID: 34083659   DOI: 10.1038/s41598-021-91287-z
20317  Kongkrongtong T, Zhang R, Kawahara M.  Rational design of heterodimeric receptors capable of activating target signaling molecules.  Sci Rep  2021  11(1):16809  PubMed ID: 34413422   DOI: 10.1038/s41598-021-96396-3
15885  Ryo Nagai, Takeru Ebihara, Kohei Kakino, Akitsu Masuda, Jian Xu, Kosuke Minamihata, Noriho Kamiya, Tatphon Kongkrongtong, Masahiro Kawahara, Hiroaki Mon, Tsuguru Fujii, Takahiro Kusakabe, Jae Man Lee  Production of an active Mus musculus IL-3 using updated silkworm-based baculovirus expression vector system  Journal of Asia-Pacific Entomology  2021  24:544-549    DOI: 10.1016/j.aspen.2021.04.011
16098  Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB.  Clinical Acquired Resistance to KRAS G12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation  Cancer Discov  2021  11(8):1913-1922  PubMed ID: 33824136   DOI: 10.1158/2159-8290.CD-21-0365
16117  Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, Chiba M, Shimoji M, Takemoto T, Arita T, Gmachl M, Hofmann MH, Soh J, Mitsudomi T  KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments  J Thorac Oncol  2021  16(8):1321-1332  PubMed ID: 33971321   DOI: 10.1016/j.jtho.2021.04.015
16769  Koya Y, Nara H, Yagi S, Ueno C, Kamohara M.  An engineered tetra-valent antibody fully activates the Tie2 receptor with comparable potency to its natural ligand angiopoietin-1  Sci Rep  2021  11(1):14021  PubMed ID: 34234265   DOI: 10.1038/s41598-021-93660-4
16774  Koga T, Suda K, Nishino M, Fujino T, Ohara S, Hamada A, Soh J, Tirunagaru V, Vellanki A, Doebele RC, Mitsudomi T.  Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study  Transl Lung Cancer Res  2021  10(8):3659-3670  PubMed ID: 34584864   DOI: 10.21037/tlcr-21-216
11561  Yamada R, Fukumoto R, Noyama C, Fujisawa A, Oka S, Imamura T.  An epidermis-permeable dipeptide is a potential cosmetic ingredient with partial agonist/antagonist activity toward fibroblast growth factor receptors.  J Cosmet Dermatol  2020  19(2):477-484  PubMed ID: 31099492   DOI: 10.1111/jocd.12997
12115  Hirai N, Sasaki T, Okumura S, Minami Y, Chiba S, Ohsaki Y.  Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers.  Front Oncol  2020    PubMed ID: 32300555   DOI: 10.3389/fonc.2020.00419
12148  David Koschut, Debleena Ray, Zhenhua Li, Emanuela Giarin, Jürgen Groet, , Ivan Alić, Shirley Kow-Yin Kham, , Wee Joo Chng, Hany Ariffin, , David M. Weinstock, , Allen Eng-Juh Yeoh, , Giuseppe Basso, , Dean Nižetić  RAS activation via CRLF2 signaling is a widespread mechanism in Down syndrome acute lymphoblastic leukemia regardless of RAS mutations  bioRxiv  2020      DOI: 10.1101/2020.02.03.931725
13011  Tanaka H, Negoro K, Koike T, Tsukamoto I, Yokoyama K, Maeda J, Inagaki Y, Shimoshige Y, Ino K, Ishizu K, Takahashi T.  Discovery and structure-activity relationships study of positive allosteric modulators of the M3 muscarinic acetylcholine receptor.  Bioorg Med Chem  2020    PubMed ID: 32386953   DOI: 10.1016/j.bmc.2020.115531
13901  Yamahira S, Heike Y.  Facile Fabrication of Thin-Bottom Round-Well Plates Using the Deformation of PDMS Molds and Their Application for Single-Cell PCR  Micromachines (Basel)  2020  11(8):748  PubMed ID: 32751967   DOI: 10.3390/mi11080748
11428  Kang JH, Miettinen TP, Chen L, Olcum S, Katsikis G, Doyle PS, Manalis SR.  Noninvasive monitoring of single-cell mechanics by acoustic scattering.  Nat. Methods  2019    PubMed ID: 30742041   DOI: 10.1038/s41592-019-0326-x
4862  Yonesaka K, Kobayashi Y, Hayashi H1, Chiba Y, Mitsudomi T, Nakagawa K.  Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.  Oncol Rep  2019  1(2):1059-1066  PubMed ID: 30483795   DOI: 10.3892/or.2018.6881
4865  Eguchi A, Nakakido M, Nagatoishi S, Kuroda D, Tsumoto K, Nagamune T, Kawahara M.  An epitope-directed antibody affinity maturation system utilizing mammalian cell survival as readout.  Biotechnol Bioeng  2019  116(7):1742-1751  PubMed ID: 30883677   DOI: 10.1002/bit.26965
4870  Udagawa H#1, Hasako S#2, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi S.  TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.  Mol Cancer Res  2019  17(11):2233-2243  PubMed ID: 31467113   DOI: 10.1158/1541-7786.MCR-19-0419
4872  Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S.  Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.  Mol Cancer Ther  2019  18(8):1366-1373  PubMed ID: 31092564   DOI: 10.1158/1535-7163.MCT-18-0976
4875  Yuki Uchiharaa, Tomoyuk iOhe, Tadahiko Mashino, Takayuki Kidokoro, Kenji Tago, Hiroomi Tamura, Megumi Funakoshi-Tago  N-Acetyl cysteine prevents activities of STAT3 inhibitors, Stattic and BP-1-102 independently of its antioxidant properties  Pharmacol Rep  2019  71(6):1067-1078  PubMed ID: 31627175   DOI: 10.1016/j.pharep.2019.05.021
11622  Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.  Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.  J Thorac Oncol  2019  14(10):1753-1765  PubMed ID: 31279006   DOI: 10.1016/j.jtho.2019.06.023
6896  Kim HJ, Kim HJ, Kim MK, Bae MK, Sung HY, Ahn JH, Kim YH, Kim SC, Ju W.  SPSB1 enhances ovarian cancer cell survival by destabilizing p21.  Biochem Biophys Res Commun  2019  510(3):364-369  PubMed ID: 30712944   DOI: 10.1016/j.bbrc.2019.01.088
12393  Futami T, Kawase T, Mori K, Asaumi M, Kihara R, Shindoh N, Kuromitsu S.  Identification of a novel oncogenic mutation of FGFR4 in gastric cancer  Sci Rep  2019  9(1):14627  PubMed ID: 31601997   DOI: 10.1038/s41598-019-51217-6
12394  Kawase T, Nakazawa T, Eguchi T, Tsuzuki H, Ueno Y, Amano Y, Suzuki T, Mori M, Yoshida T.  Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells  Oncotarget  2019  10(58):6111-6123  PubMed ID: 31692922   DOI: 10.18632/oncotarget.27222
10032  Oyama S, Kitamura H, Kuramochi T, Higuchi Y, Matsushita H, Suzuki T, Goto M, Adachi H, Kasutani K, Sakamoto A, Iwayanagi Y, Kaneko A, Nanami M, Fujii E, Esaki K, Takashima Y, Shimaoka S, Hattori K, Kawabe Y.  Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody.  Exp. Dermatol.  2018  27:14-21  PubMed ID: 27714851   DOI: 10.1111/exd.13236
4160  Koga T, Kobayashi Y, Tomizawa K, Suda K, Kosaka T, Sesumi Y, Fujino T, Nishino M, Ohara S, Chiba M, Shimoji M, Takemoto T, Suzuki M, Jänne PA, Mitsudomi T.  Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.  Lung Cancer  2018    PubMed ID: 30527195   DOI: 10.1016/j.lungcan.2018.10.019
4161  Kobayashi Y, Fujino T, Nishino M, Koga T, Chiba M, Sesumi Y, Ohara S, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.  EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.  J Thorac Oncol  2018    PubMed ID: 29410323   DOI: 10.1016/j.jtho.2018.01.009
4162  Uchihara Y, Tago K, Taguchi H, Narukawa Y, Kiuchi F, Tamura H, Funakoshi-Tago M.  Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.  Biochem. Pharmacol.  2018    PubMed ID: 29859988   DOI: 10.1016/j.bcp.2018.05.018
4163  Funahashi SI, Kawai S, Fujii E, Taniguchi K, Nakano K, Ishikawa S, Aburatani H, Suzuki M.  Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma.  J. Biochem.  2018    PubMed ID: 30239818   DOI: 10.1093/jb/mvy074
4164  Yoshida H, Yamada H, Nogami W, Dohi K, Kurino-Yamada T, Sugiyama K, Takahashi K, Gahara Y, Kitaura M, Hasegawa M, Oshima I, Kuwabara K.  Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.  Exp. Hematol.  2018    PubMed ID: 29274361   DOI: 10.1016/j.exphem.2017.12.005
4269  Hirao T, Yamaguchi M, Kikuya M, Chibana H, Ito K, Aoki S.  Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.  Cancer Sci.  2018    PubMed ID: 29121435   DOI: 10.1111/cas.13442
4471  Katayama K, Noguchi K, Sugimoto Y.  Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.  Oncotarget  2018  9(76):34240-34258  PubMed ID: 30344940   DOI: 10.18632/oncotarget.26045
15838  Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K.  TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations  Mol Cancer Ther  2018  17(8):1648-1658  PubMed ID: 29748209   DOI: 10.1158/1535-7163.MCT-17-1206
10205  Nguyen TD, Takasuka H, Kaku Y, Inoue S, Nagamune T, Kawahara M.  Engineering a growth sensor to select intracellular antibodies in the cytosol of mammalian cells.  J. Biosci. Bioeng.  2017  124:125-132  PubMed ID: 28319021   DOI: 10.1016/j.jbiosc.2017.02.017
10264  Nagata N, Iwanari H, Kumagai H, Kusano-Arai O, Ikeda Y, Aritake K, Hamakubo T, Urade Y.  Generation and characterization of an antagonistic monoclonal antibody against an extracellular domain of mouse DP2 (CRTH2/GPR44) receptors for prostaglandin D2.  PLoS ONE  2017  12:e0175452  PubMed ID: 28394950   DOI: 10.1371/journal.pone.0175452
10272  Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.  Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.  BMC Cancer  2017  17:281  PubMed ID: 28424065   DOI: 10.1186/s12885-017-3263-z
4570  Funahashi SI, Suzuki Y, Nakano K, Kawai S, Suzuki M.  Generation and characterization of monoclonal antibodies against human LGR6.  J Biochem  2017  161(4):361-368  PubMed ID: 28013222   DOI: 10.1093/jb/mvw077
4842  Kim SY, Ahn T, Bang H, Ham JS, Kim J, Kim ST, Jang J, Shim M, Kang SY, Park SH, Min BH, Lee H, Kang WK, Kim KM, Park W, Lee J.  Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.  Oncotarget  2017  8(9):15014-15022  PubMed ID: 28122360   DOI: 10.18632/oncotarget.14788
4859  Cho J, Kim SY, Kim YJ, Sim MH, Kim ST, Kim NKD, Kim K, Park W, Kim JH, Jang KT, Lee J.  Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.  Clin Transl Oncol  2017  19(10):1247-1252  PubMed ID: 28421416   DOI: 10.1007/s12094-017-1662-x
4859  Cho J, Kim SY, Kim YJ, Sim MH, Kim ST, Kim NKD, Kim K, Park W, Kim JH, Jang KT, Lee J.  Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.  Clin Transl Oncol  2017  19(10):1247-1252  PubMed ID: 28421416   DOI: 10.1007/s12094-017-1662-x
4873  Watanabe M, Nakano K, Kadin ME, Higashihara M, Watanabe T, Horie R.  CD30 Induces Heat Shock Protein 90 and Signal Integration in Classic Hodgkin Lymphoma Cells.  Am J Pathol  2017  187(1):163-175  PubMed ID: 27870927   DOI: 10.1016/j.ajpath.2016.09.007
4878  Uchihara Y, Ueda F, Tago K, Nakazawa Y, Ohe T, Mashino T, Yokota S, Kasahara T, Tamura H, Funakoshi-Tago M.  Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.  PLoS One  2017  12(8):e0183003  PubMed ID: 28806414   DOI: 10.1371/journal.pone.0183003
14040  Aihara A, Koike T, Abe N, Nakamura S, Sawaguchi A, Nakamura T, Sugimoto N, Nakauchi H, Nishino T, Eto K.  Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells  Blood Adv  2017  1(7):468-476  PubMed ID: 29296963   DOI: 10.1182/bloodadvances.2016000844
10912  Izuta S, Yamaguchi S, Misawa R, Yamahira S, Tan M, Kawahara M, Suzuki T, Takagi T, Sato K, Nakamura M, Nagamune T, Okamoto A.  Microfluidic preparation of anchored cell membrane sheets for in vitro analyses and manipulation of the cytoplasmic face  Sci Rep  2017  7(1):14962  PubMed ID: 29097751   DOI: 10.1038/s41598-017-14737-7
14690  Ogura H, Nagatake-Kobayashi Y, Adachi J, Tomonaga T, Fujita N, Katayama R.  TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity  Sci Rep  2017  7(1):5519  PubMed ID: 28717217   DOI: 10.1038/s41598-017-05736-9
4852  Miura T, Nagamune T, Kawahara M.  Ligand-inducible dimeric antibody for selecting antibodies against a membrane protein based on mammalian cell proliferation.  Biotechnol Bioeng  2016  113(5):1113-23  PubMed ID: 26479395   DOI: 10.1002/bit.25858
4860  Ishibashi T, Yaguchi A, Terada K, Ueno-Yokohata H, Tomita O, Iijima K, Kobayashi K, Okita H, Fujimura J, Ohki K, Shimizu T, Kiyokawa N.  Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.  Exp Hematol  2016  44(3):177-88.e5  PubMed ID: 26703895   DOI: 10.1016/j.exphem.2015.11.009
4867  Ichida Y, Utsunomiya Y, Tomikawa J, Nakabayashi K, Sato T, Onodera M.  Long time-course monitoring of ZFP809-mediated gene silencing in transgene expression driven by promoters containing MLV-derived PBS.  Biosci Biotechnol Biochem  2016  80(1):114-20  PubMed ID: 26252886   DOI: 10.1080/09168451.2015.1072461
14140  Stevens MM, Maire CL, Chou N, Murakami MA, Knoff DS, Kikuchi Y, Kimmerling RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero NA, Idbaih A, Wen PY, Weinstock DM, Ligon KL, Manalis SR.  Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate  Nat Biotechnol   2016  34(11):1161-1167  PubMed ID: 27723727   DOI: 10.1038/nbt.3697
4843  Trung LQ, Espinoza JL, An DT, Viet NH1, Shimoda K, Nakao S.  Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway.  Mol Nutr Food Res  2015  59(11):2143-54  PubMed ID: 26375873   DOI: 10.1002/mnfr.201500166
4849  Fujita T, Yuno M, Okuzaki D, Ohki R, Fujii H.  Identification of non-coding RNAs associated with telomeres using a combination of enChIP and RNA sequencing.  PLoS One  2015  10(4):e0123387  PubMed ID: 25874893   DOI: 10.1371/journal.pone.0123387
14974  Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I.  Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer  Clin Cancer Res  2015  21(17):4014-21  PubMed ID: 26019170   DOI: 10.1158/1078-0432.CCR-15-0016
15120  Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T.  EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs  Clin Cancer Res  2015  21(23):5305-13  PubMed ID: 26206867   DOI: 10.1158/1078-0432.CCR-15-1046
15188  Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.  Mutations in G protein β subunits promote transformation and kinase inhibitor resistance  Nat Med  2015  21(1):71-5  PubMed ID: 25485910   DOI: 10.1038/nm.3751
4836  Tomita O, Iijima K, Ishibashi T, Osumi T, Kobayashi K, Okita H, Saito M, Mori T, Shimizu T, Kiyokawa N.  Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.  Leuk Res  2014  38(3):361-70  PubMed ID: 24367893   DOI: 10.1016/j.leukres.2013.11.017
4839  Nakaya Y, Shide K, Naito H, Niwa T, Horio T, Miyake J, Shimoda K.  Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.  Blood Cancer J  2014  4:e174  PubMed ID: 24413068   DOI: 10.1038/bcj.2013.73
4850  Yoshida R1, Kawahara M, Nagamune T.  A novel platform for antibody library selection in mammalian cells based on a growth signalobody.  Biotechnol Bioeng  2014  111(6):1170-9  PubMed ID: 24338724   DOI: 10.1002/bit.25173
4851  Yidan Ma, Teruyuki Nagamune, Masahiro Kawahara  Split focal adhesion kinase for probing protein–protein interactions  Biochemical Engineering Journal  2014  90:272-278    DOI: 10.1016/j.bej.2014.06.022
4857  Kawahara M, Hitomi A, Nagamune T.  Antigen-responsive regulation of Cell motility and migration via the signalobodies based on c-Fms and c-Mpl.  Biotechnol Prog  2014  30(2):411-7  PubMed ID: 24375974   DOI: 10.1002/btpr.1861
4858  Saka K, Kawahara M, Nagamune T.  Quantitative control of intracellular signaling activity through chimeric receptors incorporating multiple identical tyrosine motifs.  Biotechnol Bioeng  2014  111(5):948-55  PubMed ID: 24222636   DOI: 10.1002/bit.25151
4866  Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H.  Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.  Mol Cancer Ther  2014  13(12):2910-8  PubMed ID: 25349307   DOI: 10.1158/1535-7163.MCT-14-0274
12522  Kato A, Fujii E, Watanabe T, Takashima Y, Matsushita H, Furuhashi T, Morita A.  Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis  J Dermatol Sci  2014  4(3):229-35  PubMed ID: 24667097   DOI: 10.1016/j.jdermsci.2014.02.009
4838  Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.  Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).  PLoS One  2013  8(10):e76551  PubMed ID: 24124571   DOI: 10.1371/journal.pone.0076551
4841  Takagi M, Sato M, Piao J, Miyamoto S, Isoda T, Kitagawa M, Honda H, Mizutani S.  ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia.  DNA Repair (Amst)  2013  12(7):500-7  PubMed ID: 23694754   DOI: 10.1016/j.dnarep.2013.04.022
4845  Nakabayashi H, Kawahara M, Tanaka K, Nagamune T.  Construction of antibody/insulin receptor chimera for growth induction of mammalian cells.  Cytotechnology  2013  65(6):945-53  PubMed ID: 23615961   DOI: 10.1007/s10616-013-9571-5
4846  Saka K, Kawahara M, Nagamune T.  Reconstitution of a cytokine receptor scaffold utilizing multiple different tyrosine motifs.  Biotechnol Bioeng  2013  110(12):3197-204  PubMed ID: 23775041   DOI: 10.1002/bit.24973
4855  Tone Y, Kawahara M, Hayashi J, Nagamune T.  Cell fate conversion by conditionally switching the signal-transducing domain of signalobodies.  Biotechnol Bioeng  2013  110(12):3219-26  PubMed ID: 23794462   DOI: 10.1002/bit.24985
4861  Saka K, Kawahara M, Teng J, Otsu M, Nakauchi H, Nagamune T.  Top-down motif engineering of a cytokine receptor for directing ex vivo expansion of hematopoietic stem cells.  J Biotechnol  2013  168(4):659-65  PubMed ID: 24070902   DOI: 10.1016/j.jbiotec.2013.09.012
16424  Nakamura M, Uehara Y, Asada M, Suzuki M, Imamura T.  Sulfated glycosaminoglycan-assisted receptor specificity of human fibroblast growth factor (FGF) 19 signaling in a mouse system is different from that in a human system  J Biomol Screen  2013  18(3):321-30  PubMed ID: 23064887   DOI: 10.1177/1087057112463820
4837  Kaneda M1, Odaka T, Suetake H, Tahara D, Miyadai T.  Teleost IL-6 promotes antibody production through STAT3 signaling via IL-6R and gp130.  Dev Comp Immunol  2012  38(2):224-31  PubMed ID: 22469658   DOI: 10.1016/j.dci.2012.02.002
4854  Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM.  Next-generation cDNA screening for oncogene and resistance phenotypes.  PLoS One  2012  7(11):e49201  PubMed ID: 23145123   DOI: 10.1371/journal.pone.0049201
4880  Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Mori S, Kamihira S, Tomonaga M, Miyazaki Y.  Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.  Int J Hematol  2012  95(2):209-13  PubMed ID: 22262141   DOI: 10.1007/s12185-012-1005-1
7791  Nakamura M, Uehara Y, Asada M, Honda E, Nagai N, Kimata K, Suzuki M, Imamura T.  Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho.  J. Biol. Chem.  2011  286:26418-23  PubMed ID: 21653700   DOI: 10.1074/jbc.M111.251140
4844  Tsuruyama T, Hiratsuka T, Jin G, Imai Y, Takeuchi H, Maruyama Y, Kanaya K, Ozeki M, Takakuwa T, Haga H, Tamaki K, Nakamura T.  Murine leukemia retrovirus integration induces the formation of transcription factor complexes on palindromic sequences in the signal transducer and activator of transcription factor 5a gene during the development of pre-B lymphomagenesis.  Am J Pathol  2011  178(3):1374-86  PubMed ID: 21356387   DOI: 10.1016/j.ajpath.2010.12.012
15721  Shen M, Siu S, Byrd S, Edelmann KH, Patel N, Ketchem RR, Mehlin C, Arnett HA, Hasegawa H.  Diverse functions of reactive cysteines facilitate unique biosynthetic processes of aggregate-prone interleukin-31  Exp Cell Res  2011  317(7):976-93  PubMed ID: 21182835   DOI: 10.1016/j.yexcr.2010.12.012
4888  Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A.  Analysis of Aurora B kinase in non-Hodgkin lymphoma.  Lab Invest  2009  89(12):1364-73  PubMed ID: 19823168   DOI: 10.1038/labinvest.2009.106
4856  Asada M, Honda E, Imamura T.  Biologically active fibroblast growth factor 1 tagged with various epitopes.  BMC Res Notes  2008  1:42  PubMed ID: 18710495   DOI: 10.1186/1756-0500-1-42
4876  Takada A, Yoshida S, Kajikawa M, Miyatake Y, Tomaru U, Sakai M, Chiba H, Maenaka K, Kohda D, Fugo K, Kasahara M.  Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D.  J Immunol  2008  180(3):1678-85  PubMed ID: 18209064   DOI: 10.4049/jimmunol.180.3.1678
14416  Yamane N, Takahashi K, Tanaka Y, Kato K, Takayama M, Ohyabu N, Shiota T, Takenaka H, Yoshida Y, Hara S, Murashi T, Nakamura E, Nishitani Y, Ishizaki J, Yamane S, Nagata K, Koizumi K, Yutsudo T, Suzuki R, Itoh T, Takemoto H.  Discovery of novel non-peptide thrombopoietin mimetic compounds that induce megakaryocytopoiesis  Biosci Rep . 2008 Oct;28(5):275-85  2008  28(5):275-85  PubMed ID: 18620546   DOI: 10.1042/BSR20080086
16421  Motomura K, Hagiwara A, Komi-Kuramochi A, Hanyu Y, Honda E, Suzuki M, Kimura M, Oki J, Asada M, Sakaguchi N, Nakayama F, Akashi M, Imamura T.  An FGF1:FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radioprotection  Biochim Biophys Acta  2008  1780(12):1432-40  PubMed ID: 18760333   DOI: 10.1016/j.bbagen.2008.08.001
2882  Maeda T, Yagasaki F, Ishikawa M, Takahashi N, Bessho M.  Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.  Blood  2005  105(5):2115-23  PubMed ID: 15514005   DOI: 10.1182/blood-2003-12-4290
4879  Nawata R, Yujiri T, Nakamura Y, Ariyoshi K, Takahashi T, Sato Y, Oka Y, Tanizawa Y.  MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation.  Oncogene  2003  22(49):7774-80  PubMed ID: 14586403   DOI: 10.1038/sj.onc.1206901
4884  Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T.  Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain  Oncogene  2002  21(16):2555-63  PubMed ID: 11971190   DOI: 10.1038/sj.onc.1205332
2559  Shimizu A, Tada K, Shukunami C, Hiraki Y, Kurokawa T, Magane N, Kurokawa-Seo M  A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells.  J Biol Chem  2001  276:11031-40  PubMed ID: 11134040   DOI: 10.1074/jbc.M003535200
4871  Feng R, Kabayama A, Uchida K, Hoshino H, Miwa M.  Cell-free entry of human T-cell leukemia virus type 1 to mouse cells.  Jpn J Cancer Res  2001  92(4):410-6  PubMed ID: 11346463   DOI: 10.1111/j.1349-7006.2001.tb01110.x
16915  Sun W, Hattori N, Mutai H, Toyoshima Y, Kimura H, Tanaka S, Shiota K.  PAL31, a nuclear protein required for progression to the S phase  Biochem Biophys Res Commun   2001  280(4):1048-54  PubMed ID: 11162633   DOI: 10.1006/bbrc.2000.4244
4832  Kawasaki K1, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M.  Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol.  J Biol Chem  2000  275(4):2251-4  PubMed ID: 10644670   DOI: 10.1074/jbc.275.4.2251
4840  Tsunekawa B, Wada M, Ikeda M, Banba S, Kamachi H, Tanaka E, Honjo M.  The binding between the stem regions of human growth hormone (GH) receptor compensates for the weaker site 1 binding of 20-kDa human GH (hGH) than that of 22-kDa hGH.  J Biol Chem  2000  275(21):15652-6  PubMed ID: 10748003   DOI: 10.1074/jbc.M001236200
4853  Odajima J, Matsumura I, Sonoyama J, Daino H, Kawasaki A, Tanaka H, Inohara N, Kitamura T, Downward J, Nakajima K, Hirano T, Kanakura Y.  Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival.  J Biol Chem  2000  275(31):24096-105  PubMed ID: 10918073   DOI: 10.1074/jbc.m001606200
3112  Yoneda A, Asada M, Oda Y, Suzuki M, Imamura T.  Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity.  Nat Biotechnol  2000  18(6):641-4  PubMed ID: 10835602   DOI: 10.1038/76487
4831  Kume A1, Ito K, Ueda Y, Hasegawa M, Urabe M, Mano H, Ozawa K.  A G-CSF receptor-gyrase B fusion gene: A new type of molecular switch for expansion of genetically modified hematopoietic cells.  Biochem Biophys Res Commun  1999  260(1):9-12  PubMed ID: 10381335   DOI: 10.1006/bbrc.1999.0859
4833  Matsuda KM, Kume A, Ueda Y, Urabe M, Hasegawa M, Ozawa K.  Development of a modified selective amplifier gene for hematopoietic stem cell gene therapy  Gene Ther  1999  6(6):1038-44  PubMed ID: 10455406   DOI: 10.1038/
4834  Xu R, Kume A, Matsuda KM, Ueda Y, Kodaira H, Ogasawara Y, Urabe M, Kato I, Hasegawa M, Ozawa K.  A selective amplifier gene for tamoxifen-inducible expansion of hematopoietic cells.  J Gene Med  1999  1(4):236-44  PubMed ID: 10738556   DOI: 10.1002/(SICI)1521-2254(199907/08)1:4<236::AID-JGM42>3.0.CO;2-2
4848  Yoneda A, Asada M, Suzuki M, Imamura T.  Introduction of an N-glycosylation cassette into proteins at random sites: expression of neoglycosylated FGF.  Biotechniques  1999  27(3):576-8  PubMed ID: 10489617   DOI: 10.2144/99273rr05
2271  Wada M, Uchida H, Ikeda M, Tsunekawa B, Naito N, Banba S, Tanaka E, Hashimoto Y, Honjo M.  The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma.  Mol Endocrinol  1998  2(1):146-56  PubMed ID: 9440818   DOI: 10.1210/mend.12.1.0054
4830  Sasaki M, Sasaki T, Enami J.  Prolactin-dependent growth and gamma-casein gene expression in Ba/F3 cells transfected with a long form of mouse mammary prolactin receptor.  Endocr J  1996  43(1):45-52  PubMed ID: 8732451   DOI: 10.1507/endocrj.43.45
4883  Palaga T, Kataoka T, Woo JT, Nagai K.  Suppression of apoptotic cell death of IL-3-dependent cell lines by ER/SR Ca2+-ATPase inhibitors upon IL-3 deprivation.  Exp Cell Res  1996  228(1):92-7  PubMed ID: 8892975   DOI: 10.1006/excr.1996.0303
4835  Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M.  RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family.  J Immunol  1995  154(7):3333-40  PubMed ID: 7897216  

Back Back Return Top Page